A Deeper Look into IL-17 and IL-23 Inhibitors in
the Management of Moderate to Severe Psoriasis:
Exploring New Pathways to Clearer Skin

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the Treatment and Management of Moderate to Severe Psoriasis: Tailoring Treatments to Achieve Improved Patient Outcomes and Quality of Life is a 3-part live webinar series that will provide attendees with the latest information in Psoriasis.

This activity is an archive from the webinar held January 12, 2018

This is Part 1 of the series focusing on the management of IL-17 and IL-23 Inhibitors

This activity is valid from February 20, 2018 to February 28, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

During this three part live webinar activity and subsequent enduring webcast and monograph, attendees will receive education that can not only assist them in developing the best strategy to improve outcomes for their psoriasis member population, but that education can also be passed along to their providers and patients (members) in an effort to better manage and support psoriasis patients, while improving outcomes, and quality of life. The webinars will explore critical aspects of the pathogenesis of psoriasis, updated safety and efficacy data on new biologic therapies that inhibit the IL-17 and IL-23 pathways, issues related to caring for patients not responding to traditional systemic treatments, strategies to manage treatment related adverse events, and strategic approaches to diagnosing and treating psoriasis. Attendees will leave with the ability to understand the disease prevalence and burden, management strategies for current and emerging therapies, combination therapy and managing side effects and co-morbidities, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.

Upon Completion of this activity, participants will be able to:

  • Design individualized treatment plans for patients with moderate to severe psoriasis using clinical safety and efficacy data that take into account quality of life and the patient’s perspectives on disease severity and measures of treatment success

  • Explore current clinical data on IL-17 and IL-23 pathway inhibitors and their respective mechanisms of action in the management of moderate to severe psoriasis

  • Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence

  • Analyze the most up-to-date diagnostic criteria and standard treatment options for moderate to severe psoriasis patients

  • Provide a strategy to identify the appropriate patient populations who will benefit from IL-17 and IL-23 pathway inhibitors in moderate to severe psoriasis

Faculty: Robert E. Kalb, MD
Clinical Professor Department of Dermatology
SUNY at Buffalo School of Medicine and Biomedical Sciences


Dr. Kalb has received Grant/Research funding from AbbVie, Amgen, Janssen, Merck, Novartis. He served as a consultant for Dermira, Janssen, Sun Pharma and on the served on the Data Safety Monitoring Board for Lilly USA. His Presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue